NICE TA660: Darolutamide with androgen deprivation therapy for treating hormone-relapsed non-metastatic prostate cancer.
NICE TA903 - Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer. (Decision date - July 2023)
NHS England drug. To be used in line with NHSE commissioning intentions.
Red Drug Classifications
1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
8. NHS England commissioned – to be used in line with NHSE commissioning intentions
